Randomized, double‐blind, placebo, and risperidone‐controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6‐week trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomized, double‐blind, placebo, and risperidone‐controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6‐week trial

Published:2019-03-25 Issue:3 Volume:11 Page:
ISSN:1758-5864
Container-title:Asia-Pacific Psychiatry
language:en
Short-container-title:Asia‐Pacific Psychiatry

Author:

Higuchi Teruhiko¹,Iyo Masaomi²,Kwon Jun Soo³,Chou Yuan‐Hwa⁴⁵,Chen Hsing‐Kang⁶,Chen Jen‐Yeu⁷,Chen Tzu‐Ting⁸,Huang San‐Yuan⁹,Lee Jung‐Sik¹⁰,Saeki Yuichi¹¹,Tanaka Hisashi¹²,Wang Tzong‐Shi¹³,Wu Bo‐Jian⁶,Katoh Takao¹⁴,Ishigouoka Jun¹⁵

Affiliation:

1. Japan Depression Center Tokyo Japan

2. Department of PsychiatryNational University Corporation Chiba University Chiba Japan

3. Department of Psychiatry, College of MedicineSeoul National University Seoul South Korea

4. Department of PsychiatryTaipei Veterans General Hospital Taipei Taiwan

5. Institute of BiophotonicsNational Yang‐Ming University Taipei Taiwan

6. Department of General PsychiatryYu‐Li Hospital Hualien Taiwan

7. Yu‐Li Veterans Hospital Hualien Taiwan

8. National Taiwan University Hospital Yunlin Branch Yunlin Taiwan

9. Tri‐service General Hospital Taipei Taiwan

10. Yongin Mental Hospital Seoul South Korea

11. Gannosu hospital Fukuoka Japan

12. Tanaka Hospital Gunma Japan

13. Department of PsychiatryTaipei Tzu Chi Hospital Taipei Taiwan

14. Department of Internal Medicine, Graduate School of MedicineNippon Medical School Tokyo Japan

15. Institute of CNS Pharmacology Tokyo Japan

Funder

Dainippon Sumitomo Pharma

Publisher

Wiley

Subject

Psychiatry and Mental health,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/appy.12354

Reference2 articles.

1. Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database

2. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive and cognitive symptoms in schizophrenia, and dual psychosis;Drugs in Context;2024-08-05

2. Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial;Psychiatry Investigation;2024-07-25

3. Valuable interaction with cognitive remediation and optimal antipsychotics for recovery in schizophrenia (VICTORY-S): study protocol for an interventional, open-label, randomized comparison of combined treatment with cognitive remediation and lurasidone or paliperidone;Frontiers in Psychiatry;2024-02-06

4. Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice;Expert Opinion on Pharmacotherapy;2022-11-02

5. Systematic literature review and network meta-analysis of lurasidone, brexpiprazole and cariprazine for schizophrenia;International Clinical Psychopharmacology;2022-07-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3